

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

CAPITAL STRUCTURE

ASX code **BDA**
Shares on issue 105.8m
Market Capitalisation ~\$48.7m

BOARD & MANAGEMENT

Mr Mark Masterson
Non-Executive Chairman

Ms Jo Patterson
Chief Executive Officer

Mr Akash Bedi
Non-Executive Director

Mr George Livery
Non-Executive Director

Mr Patrice Malard
Non-Executive Director

Mr Simon O'Loughlin
Non-Executive Director

Mr Stephen Kelly
Company Secretary

CONTACT

Level 1, 377 New South Head Rd
Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

Bod achieves strong second half medicinal cannabis sales

- **3,941 MediCabilis™ prescriptions filled during H2 CY2020 – 91% increase on H1 CY2020 (H1 CY2020 prescriptions: 2,063) and 114% increase on PCP (H2 CY2019 prescriptions: 1,844)**
- **Bod has now filled over 8,000 MediCabilis™ prescriptions since July 2019**
- **Repeat prescriptions accounted for 62% of H2 CY2020 volumes outlining patient satisfaction**
- **Ongoing growth expected across coming quarters – upward trajectory in prescription volumes set to add to Bod's growing revenue profile**

Sydney, Australia – 7 January 2021: Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited ("Bod", or "the Company") (ASX: BDA) is pleased to advise that it has achieved strong medicinal cannabis sales growth during the second half of CY2020, filling a total of 3,941 MediCabilis™ prescriptions during the six month period. This marks a 91% increase on H1 CY2020 (H1 CY2020 prescriptions: 2,063) and a 114% increase on the previous corresponding period (H2 CY2019: 1,844). Bod has now filled over 8,000 MediCabilis™ prescriptions since July 2019.

Growth in prescription volumes is attributed to continued product uptake and strong brand recognition in Australia, as well as the Company's nationwide clinical observational study (refer ASX announcement 16 July 2020). Bod has also progressed a number of educational initiatives with Australian prescribers which have assisted in generating sales.

Repeat prescriptions during the second half of CY2020 accounted for 62% of volume, highlighting patient and physician product satisfaction, as well as the benefits that MediCabilis™ continues to deliver to patients suffering from chronic conditions.




Image one: Cumulative MediCabilis™ units sold on a month by month basis

Recent growth in MediCabilis™ sales and the upward trajectory in prescription volumes have significantly added to the Company's revenue profile. Bod expects to achieve further growth over the coming months both domestically and in the UK market.

CEO Jo Patterson said: "It is very pleasing to see strong growth and continued support from patients and physicians for our MediCabilis™ product.

"MediCabilis™ is commonly prescribed for a range of chronic conditions, but most noticeably chronic pain and anxiety. To treat these kinds of conditions, patients will always require a GMP

pharmaceutical grade, standardised and consistent product. This is one of the key competitive advantages of MediCabilis™ and one of the reasons behind the Company's strong repeat prescription growth.

"We expect strong demand for MediCabilis™ to continue across Australia and this growth will continue to add to our revenue profile. Board and management look forward to updating shareholders on sales progress in the coming months."

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

This announcement was authorised for release by the Board of Directors of Bod Australia Limited.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538